Dihexa

Overview

Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) is a synthetic small peptide derivative initially developed at Washington State University by Dr. Joseph Harding and colleagues. It emerged from research into the angiotensin IV (AngIV) / AT4 receptor system and its role in memory and cognition. The compound was first described in detail in a 2013 publication in the Journal of Pharmacology and Experimental Therapeutics, where it demonstrated remarkable potency in facilitating cognitive processes in animal models.

Dihexa belongs to a family of AngIV analogs designed to resist enzymatic degradation while retaining activity at the hepatocyte growth factor (HGF) / c-Met receptor system. What distinguishes Dihexa from earlier AngIV analogs like Nle1-AngIV is its dramatically improved metabolic stability and oral bioavailability, properties achieved through strategic structural modifications that protect the molecule from aminopeptidases and other degradative enzymes.

The compound gained significant attention in the nootropic and peptide research communities following reports that it was approximately seven times more potent than brain-derived neurotrophic factor (BDNF) at promoting the formation of new synaptic connections in certain in vitro assays. This finding, while derived from cell culture models, positioned Dihexa as one of the most discussed cognitive enhancement peptides in research circles.

As of 2026, Dihexa remains an investigational compound with no approved clinical applications. All published data derives from animal studies and in vitro experiments. No human clinical trials have been registered or completed.

Structure and Sequence

Dihexa is not a traditional peptide in the strict sense but rather a peptidomimetic — a small molecule designed to mimic peptide activity while incorporating non-natural structural elements for improved pharmacological properties.

Core structure: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide

• Molecular formula: C₂₅H₃₉N₃O₅
• Molecular weight: 449.59 g/mol
• Key modifications:
  • N-terminal hexanoic acid cap (replaces natural amino acids of AngIV)
  • C-terminal 6-aminohexanoic amide (provides metabolic stability)
  • Retention of the Tyr-Ile dipeptide core critical for HGF/c-Met binding

The design rationale focused on preserving the pharmacophore of AngIV (specifically the tyrosine-isoleucine segment) while replacing metabolically vulnerable flanking residues with synthetic elements that resist peptidase cleavage. This approach yielded a compound with substantially longer half-life compared to native AngIV, which is degraded within minutes in biological systems.

Mechanism of Action

HGF/c-Met Receptor System

Dihexa's primary mechanism centers on the hepatocyte growth factor (HGF) and its receptor c-Met. Rather than directly activating c-Met, Dihexa is proposed to act as a facilitator of HGF dimerization and subsequent receptor activation. The compound appears to bind to HGF and stabilize its active conformation, lowering the threshold for c-Met signaling.

The HGF/c-Met pathway is critically involved in:

• Synaptogenesis — formation of new synaptic connections between neurons via neurotrophic signaling
• Neuronal survival — anti-apoptotic signaling in neural tissue
• Dendritic branching — increased complexity of neuronal architecture
• Neurite outgrowth — extension of axons and dendrites

Procognitive Signaling Cascade

Upon c-Met activation, Dihexa triggers a downstream cascade including:

• Phosphorylation of the scaffolding protein Gab1
• Activation of PI3K/Akt survival signaling
• Recruitment of the adaptor protein Grb2
• Activation of Ras/MAPK proliferative pathways

These pathways converge on transcription factors that upregulate genes involved in synaptic plasticity, long-term potentiation (LTP), and memory consolidation.

Relationship to AT4 Receptor Pathway

The original AngIV/AT4 receptor was later identified as insulin-regulated aminopeptidase (IRAP). While early AngIV analogs were thought to act through IRAP inhibition, Harding and colleagues proposed that the procognitive effects of AngIV and its analogs (including Dihexa) are more accurately attributed to HGF/c-Met modulation. This reinterpretation shifted the mechanistic understanding of the entire AngIV analog class.

Research Summary

Pharmacokinetics

Dihexa was specifically engineered for improved pharmacokinetic properties relative to native AngIV:

• Oral bioavailability: Demonstrated functional oral activity in rodent behavioral studies, a significant advancement over most peptide compounds
• Blood-brain barrier penetration: Inferred from behavioral efficacy following oral and systemic administration; direct measurement data is limited in the public literature
• Metabolic stability: The hexanoic acid and aminohexanoic amide modifications confer substantial resistance to aminopeptidases and carboxypeptidases
• Effective doses (animal): Active in the low nanomolar to picomolar range in vitro; oral doses of approximately 2 mg/kg in rat studies
• Half-life: Not precisely quantified in published literature, but substantially longer than native AngIV (which has a half-life of minutes)

The oral activity of Dihexa is one of its most notable pharmacokinetic features, as the vast majority of peptide-based compounds require parenteral administration due to gastrointestinal degradation.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

Dosing Schedule

Cycle Guidelines

• Cycle length: 4-8 weeks
• Preferred route: Oral (Dihexa is one of the rare peptide-based compounds with meaningful oral bioavailability)
• Timing: Consistent daily timing
• Note: Extremely limited human data exists; dosing is extrapolated primarily from animal research and community reports

Common Discussion Topics

Potency Comparisons with BDNF

The frequently cited claim that Dihexa is "7x more potent than BDNF" requires important context. This comparison derives from a specific in vitro assay measuring synaptogenesis in cultured hippocampal neurons. BDNF and Dihexa act through entirely different receptor systems (TrkB vs. c-Met), and the comparison reflects relative potency in a single assay endpoint, not overall neurotropic equivalence. In living organisms, BDNF serves numerous functions beyond synaptogenesis that Dihexa does not replicate.

Safety and Toxicity Concerns

A significant gap in the Dihexa literature is the absence of formal toxicology studies. The HGF/c-Met pathway is strongly implicated in cancer biology — c-Met is a proto-oncogene, and HGF/c-Met signaling promotes cell proliferation, survival, and migration in various tumor types. Whether chronic Dihexa administration could promote neoplastic growth remains an open and important question that has not been addressed experimentally in the published literature.

Limited Research Base

The majority of Dihexa research originates from a single laboratory group at Washington State University. While the published work is peer-reviewed and methodologically sound, the lack of independent replication by other research groups is a notable limitation. Independent confirmation of key findings, particularly the HGF/c-Met mechanism and the BDNF potency comparison, would substantially strengthen the evidence base.

Patent and Development Status

Dihexa is covered under patent filings from Washington State University. As of 2026, no pharmaceutical company has publicly announced clinical development plans for the compound. The compound remains available through research chemical suppliers but has no regulatory approval for any indication.

Related Compounds

• Cerebrolysin — Another neurotrophic compound studied for cognitive applications, though derived from porcine brain tissue rather than synthetic design
• PE-22-28 — A synthetic peptide studied for mood and cognitive effects through a different mechanism (TREK-1 channel blockade)
• BPC-157 — Shares the characteristic of acting through growth factor modulation (including HGF), though primarily studied for tissue repair rather than cognition